Mount Sinai

Running trials

• Recruiting

  Phase 3 Study of Cadonilimab Combined With Chemotherapy vs Chemotherapy in Combination With or Without Nivolumab for the 1L Treatment of Participants With HER2-negative, Previously Untreated, Unresectable or Metastatic Gastric/GEJ Adenocarcinoma

  NCT07700979· Phase 3· Source

• Recruiting

  Delayed Toxicities Post-CAR-T

  NCT07665307· Source

• Recruiting

  Safety and Efficacy of Adjunct Therapies in Adults With Type 1 Diabetes: Multicenter, Registry Study

  NCT07676565· Source

• Active, not recruiting

  MMA Embolization for Refractory Chronic Migraine

  NCT06735833· Source

• Recruiting

  A Study of PHST001 in Advanced Solid Tumors

  NCT06840886· Phase 1· Source

• Active, not recruiting

  An Observational Study Using Artificial Intelligence (AI) Algorithms on Electrocardiography (ECG), Point-of-care Ultrasound (POCUS), and Transthoracic Echocardiophy (TTE) to Estimate the Under-diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Across a Diverse Range of US Health Systems.

  NCT07062848· Source

• Recruiting

  First in Human Study of TUB-030 in Patients With Advanced Solid Tumors

  NCT06657222· Phase 1/2· Source

• Active, not recruiting

  Evaluation of a Simple-Prep Controlled Embolic

  NCT06453642· Source

• Active, not recruiting

  Investigation of the BrioVAD System for the Treatment of Left Ventricular Heart Failure

  NCT06310031· Source

• Recruiting

  A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

  NCT06662786· Phase 3· Source

• Recruiting

  PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

  NCT06445608· Source

• Recruiting

  The Effects of Successful OSA Treatment on Memory and AD Biomarkers in Older Adults Study

  NCT05988385· Source

• Recruiting

  FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

  NCT06303505· Phase 1/2· Source

• Recruiting

  Gleolan for Visualization of Newly Diagnosed or Recurrent Ovarian Cancer (OVA-302)

  NCT05804370· Phase 3· Source

• Recruiting

  A Randomized Comparison of Stage-Based Care Versus Risk Factor-Based Care for Prevention of Cardiovascular Events

  NCT06112418· Source

• Enrolling by invitation

  Guerbet Liver Fibrosis

  NCT06703450· Source

• Recruiting

  PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III

  NCT05934487· Source

• Active, not recruiting

  Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

  NCT05899608· Phase 3· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Source

• Active, not recruiting

  Phase III Study of AK112 for NSCLC Patients

  NCT06396065· Phase 3· Source

• Active, not recruiting

  ABTECT - Maintenance

  NCT05535946· Phase 3· Source

• Active, not recruiting

  Medtronic Hugo™ Robotic Assisted Surgery (RAS) System in Urologic Surgery (Expand URO)

  NCT05696444· Source

• Active, not recruiting

  A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV

  NCT05481151· Phase 3· Source

• Recruiting

  PRagmatic EVAluation of a Quality Improvement Program for People Living With Modifiable High-risk COPD.

  NCT05306743· Source

• Active, not recruiting

  P-BCMA-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Multiple Myeloma

  NCT04960579· Phase 1· Source

• Active, not recruiting

  A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

  NCT05243550· Phase 3· Source

• Active, not recruiting

  Natural History Study in Pediatric Patients With MYBPC3 Mutation-associated Cardiomyopathy

  NCT05112237· Source

• Active, not recruiting

  A Long-term Extension Study of Ustekinumab in Pediatric Participants

  NCT05092269· Phase 3· Source

• Recruiting

  Low Dose IL-2 for the Treatment of Crohn's Disease

  NCT04263831· Phase 1/2· Source

• Recruiting

  Biologics And Clinical Immunology Cohort at Sinai

  NCT04784364· Source

• Recruiting

  Parkinson's Foundation PD GENEration Genetic Registry

  NCT04994015· Source

• Recruiting

  Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

  NCT04634240· Source

• Active, not recruiting

  Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

  NCT04663347· Phase 1/2· Source

• Active, not recruiting

  A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-MutatedProstatic Neoplasms (mCSPC)

  NCT04497844· Phase 3· Source

• Active, not recruiting

  Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

  NCT04273945· Phase 3· Source

• Active, not recruiting

  HEALEY ALS Platform Trial - Master Protocol

  NCT04297683· Phase 2/3· Source

• Recruiting

  ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD)

  NCT04363684· Source

• Active, not recruiting

  PROACTIVE-HF IDE Trial Heart Failure NYHA Class III

  NCT04089059· Source

• Recruiting

  Kidney Precision Medicine Project

  NCT04334707· Source

• Active, not recruiting

  International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry

  NCT04496687· Source

• Active, not recruiting

  The CONFORMAL Early Feasibility Study

  NCT03616028· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Coronary artery disease3 recruiting
• Ovarian cancer3 recruiting
• Lung cancer2 recruiting
• Type 1 diabetes2 recruiting
• ALS (motor neurone disease)1 recruiting
• Alzheimer disease1 recruiting
• Asthma1 recruiting
• Chronic kidney disease1 recruiting
• Colorectal cancer1 recruiting
• COPD1 recruiting
• Crohn's disease1 recruiting
• Endometrial cancer1 recruiting
• Fatty liver disease (MASLD/MASH)1 recruiting
• Frontotemporal dementia1 recruiting
• Gastric and esophageal cancer1 recruiting
• Head and neck cancer1 recruiting
• Heart failure1 recruiting
• Liver and biliary tract cancer1 recruiting
• Multiple myeloma1 recruiting
• Parkinson disease1 recruiting
• Primary biliary cholangitis1 recruiting
• Sarcoma1 recruiting
• Triple-negative breast cancer1 recruiting
• Type 2 diabetes1 recruiting

Researchers

No researcher is linked here yet.

Closed trials

• Completed

  Early Feasibility Study of the Supira System in Patients Undergoing HRPCI

  NCT06087575· Source

• Terminated

  Activity and Safety of Danvatirsen and Pembrolizumab in HNSCC

  NCT05814666· Phase 2· Source

• Completed

  ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

  NCT05507216· Phase 3· Source

• Completed

  The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis

  NCT05772520· Phase 2· Source

• Terminated

  A Study to Verify the Clinical Benefit of Aducanumab in Participants With Early Alzheimer's Disease

  NCT05310071· Phase 3· Source

• Completed

  Distal Ischemic Stroke Treatment With Adjustable Low-profile Stentriever

  NCT05152524· Source

• Completed

  DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

  NCT04963231· Phase 2· Source

• Completed

  The Imperative Trial: Treatment of Acute Ischemic Stroke With the Zoom Reperfusion System

  NCT04129125· Source

• Completed

  A Study to Learn About How Well Riociguat Works, How Safe it is and How it is Used Under Real World Conditions in Patients in the United States Who Are Receiving Riociguat for High Blood Pressure in the Arteries That Carry Blood From the Heart to the Lungs (Pulmonary Arterial Hypertension, PAH)

  NCT04813926· Source

• Completed

  Roflumilast or Azithromycin to Prevent COPD Exacerbations Trial

  NCT04069312· Phase 3· Source

• Completed

  PrecISE (Precision Interventions for Severe and/or Exacerbation-Prone Asthma) Network Study

  NCT04129931· Phase 2· Source

• Completed

  Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia

  NCT03836209· Phase 2· Source

• Completed

  A Study of Erdafitinib in Participants With Advanced Solid Tumors and Fibroblast Growth Factor Receptor (FGFR) Gene Alterations

  NCT04083976· Phase 2· Source

• Completed

  Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)

  NCT04057040· Phase 2· Source

• Completed

  The EndoBARR Trial (Endometrial Bevacizumab, Atezolizumab, Rucaparib)

  NCT03694262· Phase 2· Source

• Completed

  Early Feasibility Study of the AccuCinch® Ventricular Restoration System in Patients With Prior Mitral Valve Intervention (PMVI) and Recurrent Mitral Regurgitation

  NCT03560167· Source

• Completed

  Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

  NCT03258931· Phase 3· Source

• Completed

  MIND: Artemis in the Removal of Intracerebral Hemorrhage

  NCT03342664· Source